

Progressive muscle relaxation technique in the care of anxiety and pain in the cancer patient

| | | |
|--|---|---|
| Submission date 22/11/2016 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 22/11/2016 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 04/05/2018 | Condition category Signs and Symptoms | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

Cancer patients often suffer from emotional distress such as anxiety or depression. The presence of these symptoms in combination with the physical symptoms of cancer, such as pain and nausea (feeling sick), can have a negative effect on overall quality of life. Progressive muscle relaxation is a technique which involves relaxing muscles through a two-step process: Tensing specific muscle groups followed by releasing the tension and noticing the feeling when relaxing the muscles. This exercise can be an effective way to lower overall tension and stress levels, and help people to relax when they are feeling anxious. The aim of this study is to find out whether this muscle relaxation technique can help reduce levels of anxiety and pain in cancer patients, leading to an improved quality of life.

Who can participate?

Adult cancer patients experiencing anxiety, muscle tension, sleeping difficulties, sadness, or anxiety attacks

What does the study involve?

Participants attend a single session where they learn the muscle relaxation technique. The session takes place in a comfortable room with a trained instructor, either individually or in groups. After the session, participants are encouraged to perform the technique at home at least once a day for the duration of the study. At the start of the study and then every week for a month, participants complete a number of questionnaires to assess their anxiety, pain and nausea levels. In addition, they are asked about their medication use at the same times.

What are the possible benefits and risks of participating?

There are no direct benefits or risks involved with participating in this study.

Where is the study run from?

Hospital Universitario Marques de Valdecilla and nine other hospitals in Spain.

When is the study starting and how long is it expected to run for?

February 2014 to May 2016

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr Paula Parás-Bravo

Contact information

Type(s)
Scientific

Contact name
Dr Paula Parás-Bravo

Contact details
Universidad de Cantabria
Escuela de Enfermeria
Avenida de Valdecilla s/n
santander
Spain
39008

Additional identifiers

Protocol serial number
Proyecto tesis

Study information

Scientific Title
Is the muscle relaxation technique capable of improving the quality of life of cancer patients with anxiety and pain?

Study objectives
The progressive muscle relaxation technique in its abbreviated version reduces symptoms of anxiety and pain in cancer patients, leading to improved quality of life.

Ethics approval required
Old ethics approval format

Ethics approval(s)

1. Ethical Committee of Cantabria, 29/05/2014, ref: 2014.097
2. Alcorcon Hospital Ethics Committee, 03/11/2014
3. Ethical Committee Fuenlabrada Hospital, 03/12/2014
4. Ethical Committee Getafe Hospital, 26/06/2014, ref: A13-14
5. Ethical Committee Puerta Del Hierro Hospital, 27/07/2014, ref: Huph Pi92/14
6. Ethical Committee Instituto Catalan Oncologia Badalona, 14/11/2014, ref: Jacobson 01/2014
7. Ethical Committee Instituto Catalan Oncologia Hospitalet, 10/09/2014, ref: Acta 15-14
8. Ethics Committee Salamanca Hospital, 18/07/2014

9. Sierrallama Hospital Ethics Committee, 01/08/2014, ref: 2014.097

10. Committee Etica Complex Hospitalario Navarra, 01/02/2015, ref: Pyto 2015/14

Study design

Non-randomised study

Primary study design

Interventional

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Anxiety, pain and nausea in cancer patients

Interventions

All participants receive a guided session in order to learn abbreviated progressive muscle relaxation training by following Bernstein and Borkovec. These sessions are conducted individually or in groups, according to the patients' condition. All researchers who perform the intervention are fully trained regarding the selection criteria, information provided to participants, data collection procedures and application of the technique in order to unify criteria and reduce possible inter-examiner bias. All researchers receive a written guidance document for the relaxation session. The patients perform the technique in a sitting position in rooms furnished with armchairs, cushions, pleasant lighting and an overall quiet environment. Each session last approximately 60 minutes and is divided into the following 4 parts:

1. An explanation regarding the characteristics of the abbreviated progressive muscle relaxation training by Bernstein and Borkovec
2. Application of a relaxation session
3. Answering possible questions
4. Data collection using the self-administered FACT-G questionnaire and the data collection notebook.

At the end of the session, patients are provided with information regarding the intervention consisting of a brief description of the session, based on text and images, in order to support the performance of this technique at their respective homes. Participants are advised to perform the technique at home at least once a day for the duration of the study.

Participants are followed up weekly for one month.

Intervention Type

Behavioural

Primary outcome(s)

1. Quality of life is measured using the FACT-G (Functional Assessment of Cancer Therapy - General) questionnaire at baseline and weekly for four weeks (1 month)
2. Anxiety is measured using a visual analogue scale (VAS) at baseline and weekly for four weeks (1 month)
3. Pain is measured using a visual analogue scale (VAS) at baseline and weekly for four weeks (1 month)
4. Nausea is measured by asking participants a yes/no question about their nausea levels at baseline and weekly for four weeks (1 month)

Key secondary outcome(s)

1. Analgesic use is measured through patient interviews at baseline and weekly for four weeks (1 month)
2. Anxiolytic use is measured through patient interviews at baseline and weekly for four weeks (1 month)
3. Hypnotics use is measured through patient interviews at baseline and weekly for four weeks (1 month)
4. Antidepressant use is measured through patient interviews at baseline and weekly for four weeks (1 month)

Completion date

01/05/2016

Eligibility

Key inclusion criteria

1. Age 18 years and over
2. Cancer patients
3. Experiencing anxiety, muscle tension, sleeping difficulties, sadness, or anxiety attacks
4. Provision of consent to participate

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

Patients suffering from hallucinations, delirium or other psychotic symptoms.

Date of first enrolment

01/11/2014

Date of final enrolment

01/10/2015

Locations

Countries of recruitment

Spain

Study participating centre
Hospital Universitario Marques de Valdecilla
Av. Valdecilla, 25
Santander
Spain
39008

Study participating centre
Hospital Fundación Alcorcon
Calle Budapest, 1
Madrid
Spain
28922

Study participating centre
Hospital Universitario Fuenlabrada
Calle Camino del Molino, 2
Fuenlabrada
Madrid
Spain
28942

Study participating centre
Hospital Universitario de Getafe
Carr. Madrid - Toledo, Km 12,500
Madrid
Spain
28905

Study participating centre
Complejo Hospitalario Palmplona
Calle de Irunlarrea, 3
Palmplona
Navarra
Spain
31008

Study participating centre

Hospital Sierrallana
Barrio de Ganzo, s/n
Cantabria
Spain
39300

Study participating centre
Hospital Universitario de Salamanca
Paseo de San Vicente, 88-182
Castilla y Leon
Spain
37007

Study participating centre
Instituto Catalan de Oncologia, Hospitalet
Hospital Duran i Reynals
Avinguda de la Granvia, 199-203
Barcelona
Spain
08908

Study participating centre
Instituto Catalan de Oncologia, Badalona
Hospital Duran i Reynals
Avinguda de la Granvia, 199-203
Barcelona
Spain
08908

Study participating centre
Hospital Universitario Puerta del Hierro
Calle Manuel de Falla, 1
Madrid
Spain
28222

Sponsor information

Organisation

Universidad de Cantabria

ROR

<https://ror.org/046ffzj20>

Funder(s)

Funder type

Not defined

Funder Name

Investigator initiated and funded

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 02/05/2018 | | Yes | No |